Search
Istradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigational[A184067] This region of the brain is highly involved in motor control.[A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease. … Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsEthoxzolamide
go.drugbank.com/drugs/DB00311ApprovedWithdrawnEthoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate. … Its pharmacological activity thus confers the risk for hypokalemia.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: 6-Ethoxy-1,3-benzothiazole-2-sulfonamideNintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigationalbeing [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. … [L8453] Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylateTolcapone
go.drugbank.com/drugs/DB00323ApprovedInvestigationalWithdrawnTolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. … It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Synonyms: 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone, 3,4-dihydroxy-5-nitro-4'-methylbenzophenoneInternational brands: Sen De NingDeucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalUnlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity … [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788]
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: SOTYKTU 6 mg film coated tablets, SOTYKTU® 6MG TABLETAS RECUBIERTASCanakinumab
go.drugbank.com/drugs/DB06168ApprovedInvestigationalCanakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. … Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist
Categories: Interleukin-1 BlockersProducts: IBECTA 150 MG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 4 ADET, IBECTA 150 MG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADETStrontium chloride Sr-89
go.drugbank.com/drugs/DB09498ApprovedStrontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. … Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer.[A31264] Bone metastases is a common and severe complication presented in advanced stages of the disease.
Synonyms: Strontium chloride Sr 89, Strontium chloride Sr-89Products: STRONTIUM CHLORIDE Sr-89Faricimab
go.drugbank.com/drugs/DB15303ApprovedInvestigationalHowever, another set of factors, the Tie/Ang axis, comprising the transmembrane Tie-2 receptor and its soluble ligands Ang-1 and Ang-2, has been shown to play critical roles in mediating VEGF-A-induced … [A225985, A225990, A225995] Faricimab is an IgG<sub>1</sub>-derived bispecific antibody capable of simultaneously binding to and depleting VEGF-A and Ang-2, which has been developed to improve therapeutic
Imlifidase
go.drugbank.com/drugs/DB15258ApprovedInvestigational[L28001] As a result, the risk of antibody-mediated rejection is reduced allowing kidney transplantation in highly sensitized patients to proceed.[A225836,L28001] … Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large.
Azathioprine
go.drugbank.com/drugs/DB00993ApprovedInvestigationalAzathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic … [A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesSynonyms: 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine, 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine